Specify a stock or a cryptocurrency in the search bar to get a summary
Petros Pharmaceuticals Inc
PTPIPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
Analytics
WallStreet Target Price
1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PTPI
Dividend Analytics PTPI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PTPI
Stock Valuation PTPI
Financials PTPI
Results | 2019 | Dynamics |